The complaint filed by Glancy Prongay Wolke & Rotter LLP targets a period between January 14, 2025, and May 6, 2026. Plaintiffs allege that Zoetis executives failed to disclose a sharp decline in the adoption of Librela, a canine pain medication, as veterinarians grew wary of FDA warnings concerning neurological side effects. According to the filing, the company also faced mounting pressure from lower-priced competitors for its Simparica Trio parasiticide and experienced significant market share erosion for its flagship dermatology treatments, Apoquel and Cytopoint.
In section Releases
Investors Eye Lead Role in Zoetis Securities Fraud Class Action
Investors who incurred financial losses holding Zoetis Inc. stock now have until July 27, 2026, to seek lead plaintiff status in a pending securities fraud class action. The lawsuit centers on allegations that the animal health giant misled shareholders regarding the competitive standing and safety profile of its key veterinary products.
Legal representatives claim that these omissions rendered the company's public statements about its operational health and growth prospects materially misleading. Investors seeking to participate in the litigation or those wishing to understand their rights may contact Charles Linehan at the Los Angeles-based law firm. While the deadline for lead plaintiff applications is fast approaching, current shareholders are not required to take immediate action to remain part of the class.
Comments (0)
No comments yet. Be the first!